Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. is raising capital through a primary offering of equity and pre-funded warrants under its Form S-3 shelf. The company is offering 10,003,889 shares of common stock and 1,111,111 pre-funded warrants to purchase common stock at a public offering price of $9.00 per share and $8.9999 per warrant, for an aggregate public offering price of $100,034,889. Underwriters have a 30-day option to buy up to 1,667,250 additional shares.
After $6,002,100 in underwriting discounts and estimated expenses, net proceeds are expected to be about $93.7 million, or $107.8 million if the option is fully exercised. As of March 31, 2026, net tangible book value was $0.41 per share; giving effect to the offering (excluding warrant exercise), this would increase to $1.86 per share, implying dilution of $7.14 per share to new investors. Pre-funded warrants have a $0.0001 exercise price, no expiration, and include 4.99%/9.99% beneficial ownership limits and cashless exercise features.
The company reports preliminary cash, cash equivalents and marketable securities of approximately $105.5 million at June 30, 2026, down from $150.5 million at March 31, 2026, and expects a $100.0 million milestone payment from AbbVie in July 2026. Based on its current plan and excluding this offering, it believes these resources and the AbbVie milestone are sufficient to fund operations into the second quarter of 2027, but its financial statements include a going concern explanatory paragraph. Proceeds are intended for general corporate purposes including clinical trials, pipeline development and potential commercialization of gene therapy candidates such as RGX-202 for Duchenne muscular dystrophy, for which a BLA filing via the accelerated approval pathway is anticipated in the third quarter of 2026.
REGENXBIO Inc. plans a primary offering of $100,000,000 of common stock under its shelf registration, with a 30‑day option for underwriters to purchase additional shares. Net proceeds are intended for general corporate purposes, including clinical trials, pipeline development, working capital, and potential debt repayment or acquisitions.
REGENXBIO is a clinical‑stage gene therapy company. Lead candidate RGX‑202 for Duchenne muscular dystrophy has a fully enrolled pivotal Phase III cohort (n=30) with positive topline data, and a biologics license application is targeted for the third quarter of 2026 using the FDA’s accelerated approval pathway.
The company expects cash, cash equivalents and marketable securities of approximately $105.5 million as of June 30, 2026, versus $150.5 million on March 31, 2026, and anticipates a $100.0 million AbbVie milestone in July 2026. It believes these resources will fund operations into the second quarter of 2027, while recent financial statements and risk disclosures state substantial doubt about the ability to continue as a going concern.
REGENXBIO Inc. Chief Executive Officer Simpson Curran reported routine equity compensation activity in company stock. On December 31, 2025, Curran acquired 951 shares of common stock at $6.9955 per share through the Employee Stock Purchase Plan (ESPP) for the July 1–December 31, 2025 purchase period, exempt under Rule 16b-3(c).
On June 30, 2026, Curran acquired an additional 1,453 shares at $10.18 per share via the ESPP for the January 1–June 30, 2026 purchase period. In line with the ESPP, these shares were bought at 85% of the relevant closing prices. On July 1, 2026, 6,818 shares were withheld at $13.09 per share to cover taxes upon vesting of restricted stock units granted on July 1, 2024, a non-market, tax-withholding disposition. After these transactions, Curran directly owned 338,053 shares of REGENXBIO common stock.
REGENXBIO Inc. Chief Medical Officer Steve Pakola exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options for 2,161 shares of common stock at $7.86 per share, then sold 2,161 shares in an open-market sale at $13.64 per share.
These transactions were made pursuant to a Rule 10b5-1 trading plan, indicating they were pre-scheduled. After the sale, he directly holds 213,009 shares of common stock and 64,812 stock options that remain exercisable.
REGENXBIO filed Amendment No. 2 to its Schedule TO reporting final results of an employee Exchange Offer to swap eligible outstanding options for replacement options. The Offer expired July 1, 2026; 184 eligible holders tendered options.
The Company accepted Eligible Options to purchase 1,940,394 shares (≈67.0% of shares underlying Eligible Options). All tendered options were cancelled effective July 2, 2026, and the Company granted Replacement Options to purchase 775,401 shares with an exercise price of $13.28 per share (closing Nasdaq price on July 2, 2026), under the 2025 Equity Incentive Plan.
REGENXBIO Inc. Chief Medical Officer Steve Pakola reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 36,725 shares of Common Stock at $7.86 per share and sold a total of 56,333 shares in open-market transactions at weighted average prices of $12.86 and $11.04 per share.
After these transactions, he directly holds 249,734 shares of Common Stock and 66,973 remaining stock options. One of the sales was effected under a Rule 10b5-1 trading plan, indicating it was pre-scheduled under SEC rules rather than timed discretionarily.
RGNX Rule 144 notice reporting a proposed sale of 43,206 shares of Common Stock tied to an Exercise of Stock Options, scheduled 07/01/2026. The filing also lists prior 10b5-1 sales by Stephen Pakola: 19,608 shares on 06/29/2026 for $216,560.60 and 15,309 shares on 05/11/2026 for $168,737.84.
REGENXBIO Inc. amends its Schedule TO to report updates to an Exchange Offer that permits certain non-executive employees to exchange eligible outstanding stock options for replacement options under the terms of the company’s Offer to Exchange dated June 3, 2026. The amendment includes communications, FAQs, and plan documents; other Schedule TO disclosures remain unchanged.
REGENXBIO Inc. reported that it earned a $100 million milestone payment from AbbVie after dosing the first patient in the Phase IIb/III NAAVIGATE trial of investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The payment is tied to REGENXBIO’s 2021 collaboration and license agreement with AbbVie and is expected to be received in July 2026. NAAVIGATE will evaluate a one-time gene therapy dose of 1.0x1012 genome copies per eye in approximately 135 U.S. participants with non-proliferative diabetic retinopathy, with a primary endpoint of more than a two-step improvement on the diabetic retinopathy severity scale at one year. REGENXBIO also plans to present long-term data from its ALTITUDE and wet AMD studies and to announce topline pivotal trial data for sura-vec in wet AMD with AbbVie in Q4 2026.
JPMorgan Chase & affiliates reported beneficial ownership of 2,279,362 shares of REGENXBIO Inc. The filing, an amendment to a Schedule 13G/A, shows those shares represent 4.4% of the outstanding common stock (CUSIP 75901B107). The report attributes 2,104,445 shares of sole voting power and 2,279,362 shares of sole dispositive power. Multiple JPMorgan entities are named as holders. The filing is signed by a JPMorgan vice president.